Table 3.

2–4 adverse events as observed in the intention to treat population, n = 29.

				Other CNS tumors
	Adverse event	Ependymoma (n = 8)	High grade glioma (n = 5)	Low grade glioma (n = 11)	Other (n = 5)	Total (n = 21)
Hematologic	Neutropenia	6 (75%)	2 (40%)	5 (46%)		7 (33%)
	Grade 3	5 (63%)		2 (18%)		2 (10%)
	Grade 4		1 (20%)	3 (27%)		4 (19%)
	Lymphopenia	3 (38%)	3 (60%)	5 (46%)	1 (20%)	9 (43%)
	Grade 3	2 (25%)	1 (20%)	1 (9%)		2 (10%)
	Grade 4			1 (9%)		1 (5%)
	Anaemia	4 (50%)	1 (20%)	4 (36%)		5 (24%)
	Grade 3		1 (20%)	2 (18%)		3 (14%)
	Febrile neutropenia	1 (13%)		1 (9%)		1 (5%)
	Grade 4	1 (13%)		1 (9%)		1 (5%)
Non-hematologic	ALAT/ASAT		1 (20%)	5 (46%)	2 (40%)	8 (38%)
	Grade 3		1 (20%)	4 (36%)	2 (40%)	7 (33%)
	Mucositis	1 (13%)		2 (18%)		2 (10%)
	Grade 3			1 (9%)		1 (4%)
	Diarrhea		1 (20%)	1 (9%)	1 (20%)	3 (14%)
	Other AE	1 (13%)	2 (40%)	3 (27%)	2 (40%)	7 (33%)
	Grade 3			1 (9%)	1 (20%)	2 (10%)

Data reflect n(%) of patients, referring to the predominantly observed AE (include grade 2–4). The bolded values are the cumulative frequency of grade 2–4 toxicity (as mentioned in the legend).